Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FoamPartner was a Swiss foam technology company focused on polyurethane-based specialty foams and engineered material solutions for industrial, mobility, comfort, consumer, and selected healthcare applications. Its portfolio included technical foams, comfort foams, and customized converted foam products used in areas such as filtration, sealing, packaging, bedding, automotive interiors, and medical-related foam components. FoamPartner was not a biotech or pharmaceutical developer and did not operate a drug pipeline; rather, it supplied advanced foam materials that could be incorporated into healthcare and medical products. The company was acquired by Recticel in March 2021 and later became part of Carpenter Co. through Carpenter's acquisition of Recticel's Engineered Foams division in June 2023. As a result, FoamPartner now appears to persist primarily as a legacy brand or former business within Carpenter's engineered foams operations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on FoamPartner.